Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) Total Receivables: €36.29 Mil (As of Dec. 2025)


FRA:FDY Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd FRA:FDY
69 GF Score
Price €0.25
GF Value €0.24
! 2 Warning Signs
View Full Analysis

What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Total Receivables?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co FRA:FDY 69 Total Receivables is €36.29 Mil as of Dec. 2025. GuruFocus rates FRA:FDY with a GF Score™ of 69/100 and a GF Value™ of €0.24. The stock has 2 warning signs investors should review.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Total Receivables for the quarter that ended in Dec. 2025 was €36.29 Mil.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Total Receivables Related Terms

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Total Receivables Historical Data

* Premium members only.

The historical data trend for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Total Receivables Chart

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 93.99 92.62 80.14 61.97 36.29

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Quarterly Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 67.25 61.97 53.19 43.98 36.29
FRA:FDY
69GF Score
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd FRA:FDY
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €36.29 Mil mean?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) has a Total Receivables of €36.29 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co and its competitors.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Total Receivables too high?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current Total Receivables is €36.29 Mil. Overall, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Total Receivables compare to ZTS and UTHR?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Total Receivables of €36.29 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co and its competitors. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current Total Receivables is €36.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock overvalued right now?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) has a current Total Receivables of €36.29 Mil. The stock's GF Value™ is €0.24, compared to a current price of €0.25 — trading 5% above its estimated fair value. The current Total Receivables is €36.29 Mil. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY), the current Total Receivables is €36.29 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock appears to be overvalued. The current stock price of €0.25 is trading 5% above its estimated GF Value™ of €0.24.

Key valuation signals for FRA:FDY:

  • Total Receivables: €36.29 Mil
  • GF Value™: €0.24 vs. price of €0.25 (5% above fair value)
  • GF Score™: 69/100 with 2 warning signs

No single metric tells the full story. See the FRA:FDY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Business Description

Other Exchanges 01349:Hong Kong688505:China
Address 308 Cailun Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai, CHN, 201210
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. The company has launched it's four types of photodynamic drugs in China market, namely hematoporphyrin, aminolevulinic acid hydrochloride, Verteporfin and Hemoporfin. Geographically, it derives revenue from Mainland China.
69GF Score

Get the complete analysis for FRA:FDY

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.25
Price
€0.24
GF Value